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INTRODUCTION
Prognosis of patients with gastric cancer is in-
fluenced by the presence of metastasis2,12,13,24, lymph 
nodal status has been correlated as the most impor-
tant individual prognostic factor20. There wereearly 
gastric cancer patients, treated radically, who died of 
recurrence19. There also are reports that D2 lymphad-
enectomy improves survival even in pN0 patients19. 
These may be due at least in part to the presence of 
lymph node micrometastasis at the time of resec-
tion. Although it is not consensual, micrometastasis 
can be defined as  one single cell or a cluster of 
malignant cells inside of the lymph node that are not 
visualized by routine methods, but only by special 
dies, as immunohistochemical AE1-AE3 techniqu
es1,4,6,11,18,29,33,35,36,38. In order to clarify this issue we 
studied 28 patients prospectively, treated by radical 
surgery, minimum of 30 lymph nodes resected from 
D2 lymphadenectomy and 43 lymph nodes from modi-
fied D3 lymphadenectomy.
METHODS 
One hundred eighteen patients were treated by 
surgery at Department of Gastroenterology, at the 
University of São Paulo School of Medicine, São 
Paulo, Brazil, from February 1998 to October 2000. 
The inclusion criteria were: 1. endoscopic confirmed 
biopsy of gastric adenocarcinoma, without previous 
treatment; 2. no previous malignancies or abdomi-
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ABSTRACT – Background - Micrometastasis is a single or a cluster of malignant cells inside the lymph node that are not detected by routine histopatho-
logical sections. Micrometastasis is related to poorer prognosis in many gastric cancer studies the real significance of these cells is still controversial. 
Aim – To evaluate if lymph node micrometastasis is a significant independent prognostic factor and important risk factor for recurrence in gastric 
cancer. Methods - A total of 1290 lymph nodes from 28 patients with gastric cancer, since 1998 until 2003, treated by radical resection (D2 and 
modified D3 lymphadenectomies) were studied. Three sections per lymph node were stained by Hematoxilin-Eosin, histochemical (AB-PAS) and 
immunohistochemical (AE1-AE3) techniques. Kaplan-Meier’s survival curves and Log-rank/Cox tests were used in order to compares lymph node 
micrometastasis positivity, depth (pT) and location of tumor in gastric wall, histologic type, lymphatic, vascular and perineural invasion, lymph 
node status (pN) and stage. Results - There were worse prognosis and recurrence in patients with positive lymph node micrometastasis related to 
vascular and perineural invasions, advanced lymph node status and advanced stages. Conclusion - Lymph node micrometastasis seems to be a 
significant independent prognostic factor and important risk factor for recurrence in gastric cancer, in a context of radical D2 lymphadenectomy
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nal surgery or neoadjuvant treatment; 3. no distant 
metastasis detected by X-ray, ultrasound, CT-scan or 
visible, palpable or frozen sections biopsies confirmed 
from liver, peritoneum or lymph nodes classified as 
M (JGCA 1998) (or M1 LYM) (UICC TNM 1997) or 
even other location different from esophagus, duode-
num, greater or lesser omentum; 4. no severe systemic 
illness. The main objectives in this coort of patients 
are select patients with endoscopic and biopsy proved 
diagnose of gastric cancer, to be submitted to total or 
subtotal radical gastrectomy D2 lymphadenectomy 
(JGCA 1998), staged previously or during surgery 
free of peritoneal, liver and distant lymph node me-
tastasis. We prospectively correlate the histochemical 
and immunohistochemical (AB-PAS/AE1-AE3) detec-
tion of lymph node micrometastasis with clinical and 
pathological features as: age, gender, tumor size, depth 
and location of the tumor in the gastric wall, type of 
lymphadenectomy, type of gastrectomy, histologic 
type of tumor, lymphatic, vascular and perineural 
invasion, lymph nodal status, stage studied by (1997 
UICC TNM) and 1998 JGCA classifications and 
follow-up survival curves.
Data of 28 patients who underwent potentially cura-
tive resection for gastric cancer from February 1998 to 
October 2000 were admitted to study by fulfilling the 
inclusion criteria. These patients were closely followed 
until November 2003; the median length of follow-up 
was 25 months. Routine follow-up consisted of physical 
examination, laboratory test (including CEA, CA19.9 
levels), endoscopy, chest radiography, abdominal and 
pelvic ultrasonografy and abdomen (CT) computed 
tomography or diagnostic videolaparoscopy in case of 
suspicion of recurrence. Follow-up intervals vary from 
one, to six months depending on the stage and months of 
follow-up or as needed. 
Radical gastrectomy and lymphadenectomy were per-
formed in all cases.
However immunohistochemical analysis was per-
formed exclusively in negative H&E staining technique 
concerning metastatic invasion. Lymph nodes were studied 
based in three sections by H&E, AB-PAS and AE1-AE3 
techniques. Mucines were  treated by 1% periodic acid, 
schiff reagent and alcian blue in pH 2.5 and the malignant 
cells were  detected in purple. Antibodies against human 
cytokeratins AE1-AE3 (Dako Corporation, Carpinteria, CA 
93013 USA) were  used in order to identify the cytokera-
tins of malignant cells inside lymph nodes (peroxidase-
antiperoxidase technique). Endogenous peroxidasis was 
blocked. Dark brown insolvable precipitate was formed 
peripherically around malignant cells (Figure 1).
Statistical analysis
Lymph nodes micrometastasis positivity and clini-
copathological factors were compared, with special 
reference to prognosis and survival curves. Statisti-
cally significant differences were analyzed with the 
two-tailed χ2 test, Student´s t test or Mann-Whitney 
test. Kaplan-Meier’s survival curves and Log-rank/
Cox tests were used. The risk factors were determined 
by means of logistic regression analysis. Forward step-
wise selection with a likeness ratio test was used for 
selecting variables. The odds ratio in logistic regression 
analysis was defined as the ratio of the probability that 
an event will occur to the probability that it will not 
occur. The prognostic power of variables was expressed 
by calculation of a relative risk or odds ratio with 95% 
confident interval. P<0.05 was considered statistically 
significant. All statistical analyses were carried out with 
the SPSS 12.0 for Windows program (SPSS, Chicago, 
Illinois, USA).
RESULTS
The mean age of the patients was 61.6 years (range, 
35-77 years), with peak incidence in the sixth decade. The 
total number of resected lymph nodes was 1290, the aver-
age of D2 lymphadenectomy was 37.2, median 33 (30-50), 
the average of modified D3 (D2+ α) was 62.1, median 61.5 
(43-86) (Table 1).
The overall average of resected lymph nodes was 46.1, 
median 46 (30-86). According to 1998 JGCA (2nd edition) 
stage classification11 stained by H&E 17.9% of patients 
were stage IA, 14.3% were stage IB, 10.7% were stage 
II, 21.4% were stage IIIA, 28.6% were stage IIIB and 
7.1% were stage IV. According to 1997 UICC TNM (5th 
edition)37 stage classification stained by H&E 17.9% of 
patients were stage IA, 14.3% were stage IB, 10.7% were 
stage II, 32.1% were stage IIIA, 10.7% were stage IIIB and 
14.3% were stage IV (Table 2). 
FIGURE 1 - Lymph node micrometastases detected by immuno-
histochemistry (AE1/AE3 x400)
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From 1290 lymph nodes retrieved of 28 patients, 152 
(11.8%) lymph nodes were positively detected by hematoxi-
lin-eosin staining (H&E) and 1138 (88.21%) were negative. 
After H&E technique all 1228 remaining lymph nodes were 
sectioned three times again and 197 (16%) lymph nodes were 
positive for AB-PAS histochemical staining. After AB-PAS 
technique, AE1-AE3 was performed and 1216 lymph nodes 
were studied by three sections and 225 (18.5%) lymph nodes 
were positive for AE1-AE3 technique. There were 4.8% 
and 5.7% losses in lymph nodes number, respectively in 
histochemical and immunohistochemical techniques, mostly 
by technical staining/sectioning problems and small size of 
lymph nodes. From 28 patients studied, there were 13 pa-
tients (46.4%) who had at least one positive lymph node for 
micrometastasis stained by histochemical technique among 
H&E negative lymph nodes.
From same 28 patients studied, there were 15 patients 
(53.6%) who had been stained positive, for micrometastasis 
at this time by immunohistochemical technique among 
H&E negative lymph nodes cases.
The final stage, after detection of lymph node micrometas-
tasis by special techniques: AB-PAS and AE1-AE3 that was 
not identified in routine staining H&E were upstaged (Table 2). 
The overall survival average rate was 47.1%, limited 
to 69 months. Regarding to AE1-AE3 technique, for 15 
patients with detected lymph node micrometastasis the 
survival average rate was 21.5% (28.2 months, limited 
to 63 months) For 13 patients with not detected lymph 
node micrometastasis the survival average rate was 69.2% 
(51.6 months, limited to 69 months). At the time of the 
final follow up 11 patients (39.3%) were still alive, 3 
(10.7%) were lost to follow-up and 14 (50%) died from 
recurrence. Occult lymph node micrometastasis in rou-
tine H&E detected by immunohistochemical technique 
(AE1-AE3) had worse prognosis (Log-rank/Cox tests 
p<0.05). The presence of lymph node micrometastasis 
had prognostic significance in patients with gastric cancer 
in this coort (Figure 2).
Vascular and perineural invasions, lymph nodal status, 
stage and survival were correlated to positive lymph node 
micrometastasis. The survival curves were performed and 
patients with lymph node micrometastasis had poorer 
prognosis (Figure 2).
TABLE 1 -  Clinical and pathological characteristics of gastric 
cancer patients with and without lymph node (Ln) 
micrometastasis, univariate analysis results
Variable Positive Ln 
micrometastasis
Negative Ln 
micrometastasis
P Value
Staining AB-PAS AE1-AE3 AB-PAS AE1-AE3
Age (years) 59.3±12.6 61.0±12.6 63.4±10.5 62.2±10.6 ns
Gender
Male (18) 8 10 10 8
Female (10) 5 5 5 5 ns
Tumor size  
(max diameter  in cm)      
6.2±3.2 5.8±3.2 4.7±3.0 4.5±2.9 ns
pT (depth of invasion)
pT1 (5) 1 2 4 3
pT2 (7) 2 2 5 5
pT3 (15) 10 11 5 4
pT4 (1) 0 0 1 1
Total (28) 13 15 15 13 ns
Location of  tumor in 
stomach  
Upper (4) 2 2 2 2
Middle (6) 4 5 2 1
Lower (14) 4 5 10 9
Whole (4) 3 3 1 1 ns
Lymphadenectomy
D2 (18) 7 9 11 9
D3 (10) 6 6 4 4 ns
Type of Gastrectomy
Total (15) 9 10 6 5
Subtotal (13) 4 4 9 9 ns
Histological type 
Differentiated(7) 5 4 2 3
Undifferentiated (21) 11 11 10 10 ns
Lymphatic invasion
Positive (10) 7 8 3 2
Negative (18) 6 7 12 11 ns
Vascular invasion
Positive (4) 4 4 0 0
Negative (24) 9 11 15 13 P<0.05
Perineural invasion
Positive (14) 10 11 4 3
Negative (14) 4 3 11 10 P<0.01
pN (lymph node inva-
sion/JGCA)
pN0 (8/7)* 0 0 8 7
pN1 (7) 3 3 4 4
pN2 (9/8)* 7 6 2 2
pN3 (4/6)* 3 6 1 0
Total (28) 13 15 15 13 P<0.01
pN (lymph node inva-
sion/UICC)
pN0 (8/7)* 0 0 8 7
pN1 (10/9)* 5 4 5 5
pN2 (4/6)* 3 6 1 0
pN3 (6) 5 5 1 1
Total (28) 13 15 15 13 P<0.01
Stage (JGCA)
IA (4/3) 0 0ª 4 3ª
IB (5) 1 1ª 4 4ª
II (1) 0 0ª 1 1ª
IIIA (6/5) 4 3ª 2 2ª
IIIB (8) 5 5ª 3 3ª
IV (4/6) 3 6ª 1 0ª
Total (28) 13 15 15 13 P<0.05ª
* - pN variable changes according to staining techniques (AB-PAS/AE1-AE3)
ª - Stage is related to statistical difference (P<0.05) between positive and negative 
Ln micrometastasis only in AE1/AE3 staining
ns – not significant
TABLE 2 - Stage and upstage based on H&E, AB-PAS and 
AE1-AE3 staining and 1998JGCA/1997 UICC TNM 
classifications
CLASSIFICATION JGCA UICC JGCA UICC JGCA UICC
STAINING H&E H&E AB-PAS AB-PAS
AE1-
AE3
AE1-
AE3
S 
T
 A
 G
E
 
IA 5(17,9%) 5(17,9%) 4(14,3%) 4(14,3%) 3(10,7%) 3(10,7%)
IB 4(14,3%) 4(14,3%) 5(17,9%) 5(17,9%) 5(17,9%) 6(21,4%)
II 3(10,7%) 3(10,7%) 1(3,6%) 1(3,6%) 1(3,6%) 1(3,6%)
IIIA 6(21,4%) 9(32,1%) 6(21,4%) 8(28,6%) 5(17,9%) 6(21,4%)
IIIB 8(28,6%) 3(10,7%) 8(28,6%) 3(10,7%) 8(28,6%) 5(17,9%)
IV 2(7,1%) 4(14,3%) 4(14,3%) 7(25%) 6(21,4%) 7(25%)
Numbers in bold show stage changing
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 DISCUSSION
It is well established that depth of tumor invasion in 
gastric wall (pT), lymph node invasion (pN) and distant/
peritoneal metastasis (pM) are important prognostic fac-
tors in gastric cancer2,12,13,24. Lymph nodal invasion can 
be detected from 36% to 54% of all cases of gastric can-
cer19,20,33,38. Prognosis is related to lymph nodal status19. 
“Residual tumors” and remnant positive lymph nodes left 
behind can lead to “recurrence” in gastric cancer. Recur-
rence can occur even in early gastric cancer treated with 
radical resections, as reported in 1996, by Maehara et al.19, 
34 patients died of recurrence, part of them due to lymph 
node micrometastasis. 
Micrometastasis can be defined by a single malignant 
cell or a cluster of malignant cells inside lymph node not 
detected by routine techniques as H&E, but only detected 
by special techniques as histochemical and immunohis-
tochemical staining1,4,6,11,18,29,31,33,35,36,37,38. There are others 
definitions for micrometastasis as malignant cells cluster 
smaller than 2 mm in diameter32, smaller than 0.5 mm27 
and 5 or less cells15, all of them with stromal reaction such 
as granulation or desmoplastic tissue. In the other hand 
microinvolvement can be described as individual tumor 
cells without stromal reaction32.
There are authors that do not agree that might be a 
statistical difference in prognostic significance of patients 
with and without lymph node micrometastasis3,5,14,22,23,30,34. 
Stachura et al.34, in 1998, after had studied retrospectively 
40 patients with early gastric cancers for the presence of 
micrometastasis in regional lymph nodes by cytokeratin 
18 immunostaining related that micrometastasis had no ef-
fect on patients survival and takes more than the diagnosis 
FIGURE 2 - Survival curve for gastric cancer patients with 
lymph node micrometastasis (continuous line) 
was lower compared with those without lymph 
node (interrupted  line) detected micrometastasis 
(P<0.05) (Cox)
of micrometastasis alone to estimate its real prognostic 
significance in theirs series. Fukawaga et al.5, in 2001, re-
ported a rate of 35.5% micrometastasis among 107 patients 
classified as pT2pN0M0 (JGCA 1998) detected by immu-
nohistochemical AE1-AE3 staining, treated by D2, there 
was difference between infiltrative and expansive tumors 
(P=0.02) related to detected micrometastasis, greater in the 
first one, but not in survival or prognosis between patients 
with and without detected micrometastasis. Morgagni et 
al. in 200122 and 200323 reported large number of patients 
with early gastric cancer, treated radically, that were not 
influenced by micrometastasis presence at all, in other 
words, there was no difference in survival or prognosis for 
such early gastric cancer patients.
Reversely, there are several authors that agree that there 
is significant difference in prognostic and survival among 
patients with and without lymph node micrometastasis 
8,9,10,17,19,26,28,39. 
Ishida et al.9, in 1997, reported 2446 lymph nodes 
removed from 109 gastric cancer patients stained with he-
matoxilin-eosin, Alcian blue in combination with periodic 
acid-Schiff stain and antibodies against cytokeratin and car-
cinoembryonic antigen (CEA). Metastases were confirmed 
in 230 lymph nodes (9.4%) stained with H&E, an additional 
201 lymph nodes (17.6%) had micrometastasis identified 
only by immunostaining for cytokeratin (197 lymph nodes) 
and/or CEA. Adenocarcinomas with micrometastasis 
had significantly worse prognoses at Stage II. Between 
the two histologic types of gastric carcinoma established 
by Lauren16, the diffuse type had more micrometastasis 
than the intestinal type. The presence of micrometastasis 
in lymph nodes is an indispensable factor in determining 
the prognosis of gastric carcinoma patients. Cai et al.2, in 
2000, examined 1945 lymph nodes of 79 patients with 
submucosal gastric cancer by two consecutive sections for 
H&E and immunostaining with anticytokeratin antibody 
(CAM 5.2), and demonstrated a lesser 5-year survival in 
the group of patients with micrometastasis in lymph nodes. 
Harrison et al.8, in 2000, related a retrospective review of 
25 patients, from 1981 to 1998, resected for T1-4N0M0 
gastric and gastroesophageal junction adenocarcinoma who 
underwent immunohistochemical analysis with CAM 5.2, 
the median number of lymph nodes resected was 7(1-33), 
the median follow-up time was 25 months (range 4-195) 
with an overall survival rate of 55%. For patients with 
evidence of lymph node micrometastasis (n=9), the 5-year 
survival rate was significantly decreased (35%), compared 
to a 66% 5-year survival rate for negative patients (n=16, 
P=0.05). The presence of immunohistochemical detected 
lymph node micrometastasis correlates with worse prog-
nosis for patients with histologic negative gastric cancer 
lymph nodes and immunohistochemical techniques may 
be a useful additional staging modality in this subset of 
patients. Ishigami et al.10, in 2003 reported 4203 lymph 
nodes examined retrospectively, from 180 gastric cancer 
patients and not detected any micrometastasis in submu-
cosal gastric cancer patient who underwent lymph node 
dissection. Gastric cancer patients with more than six 
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metastatic lymph nodes all had nodal micrometastasis. 
Patients who were detected positive for micrometastasis 
had a significant poorer survival rate than those without 
micrometastasis (P<0.05)
Because most of studies were done retrospectively and 
patients submitted to several adjuvant treatments, it is pos-
sible that there is still a role for a rigid quality-controlled 
lymphadenectomy and prospective study to elucidate this 
issue. Even after curative resections, recurrence can occur 
in patients with early gastric cancer16. Gotoda et al.7 stud-
ied more than 5,000 early gastric cancer patients who had 
undergone gastrectomy with lymph node dissection at the 
National Cancer Center Hospital and the Cancer Institute 
Hospital in Tokyo and none of the 1230 well differentiated 
intramucosal of less than 30 mm diameter regardless of 
ulceration findings were associated to metastases nor the 
929 early lesions without ulceration regardless tumor size. 
None of the 145 differentiated adenocarcinomas of less than 
30-mm-diameter without lymphatic or venous permeation 
were associated with metastases. Based in risk factors and 
field evidence by large number of patients a gastric cancer 
guideline in Japan was built25. 
Lymphatic system has an important role in spread of 
gastric cancer metastasis, as well as of lymph node micro-
metastasis, mainly in undifferentiated histological types, 
restricted to blue nodes and lymph nodes within the dye 
flow area of patent blue used in sentinel node navigation 
surgery for early gastric cancers21. 
Apart from the clinical and pathologic prognostic factors 
in gastric cancer, others molecular biological studies have 
suggested new prognostic factors that are now being exten-
sively investigated: growth factors and receptors (epithelial 
growth factor, transforming growth factor T-ß1 receptor); 
oncogenes and suppressor genes (c-erb B2, ras, HST-1, 
K-sam, c-met, p53, DCC, Rb P21 and nm23); cell adhesion 
molecules (integrins, cadherin, immunoglobulin superfam-
ily, CD44); chromosome deletion of 1q, 5q, 7p, 17p; tissue 
inhibitor of metalloproteinasis and urokinasis plasminogen 
activator and microsatellite instability among others.
CONCLUSION
Lymph node micrometastasis seems to be a significant 
independent prognostic factor and important risk factor for 
recurrence in gastric cancer, in a context of radical lymphad-
enectomy. Immunohistochemical AEI-AE3 techniques may 
disclose occult lymphnode micrometastasis and so contribute 
to refine pathological staging in gastric cancer.
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RESUMO – Racional – Micrometástases são um conjunto de células malignas dentro de linfonodo que não são detectadas pelos exames histopatológicos 
de rotina. Elas são relacionadas a prognóstico mais pobre em muitos estudos sobre câncer gástrico, mas a real significância dessas células permanece 
controversa. Objetivo – Avaliar se micrometástase linfonodal é um fator independente de prognóstico e importante para detectar a recurrência do 
câncer gástrico. Métodos -  Um total de 1290 lifonodos de 28 pacientes com câncer gástrico, de 1998 a 2003, tratados com operações radicais (D2 
e D3 modificadas) foram revistos. Três secções por linfonodo foram corados por Hematoxilina-Eosina, histoquímica (AB-PAS) e imunoistoquímica 
(AE1-AE3). Curvas de sobrevida de Kaplan-Meyer e teste de Log-rank/Cox foram usados para comparar positividade das imcrometástases, pro-
fundidade (pT) e localização tumoral na parede gástrica, tipo histológico, invasão linfática, vascular e perineural, estado linfonodal  (pN) e estádio 
onde se encontra a doença. Resultados – Houve pior prognóstico e recurrência nos pacientes com linfonodos com micrometástases  relacionadas 
às invasões vascular e perineural , avançado estado de invasão linfática e estadiamento mais elevado. Conclusão – Micrometástase parece ser 
importante e independente fator de risco para recurrência no câncer gástrico no contexto das linfadenectomias radicais D2. 
DESCRITORES – Câncer gástrico. Prognóstico Clínico Dinâmico. Classificação. 
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